Changing the way the world sees coronary artery disease

Artrya is a global medical technology company that is leading the world in cardiac image analysis

Beating heart disease

Artrya (ASX:AYA) is changing how the world diagnoses and therefore treats coronary artery disease. We partner with healthcare delivery systems to help implement new cardiac care models that can rule out (or in) coronary artery disease, at speed, for patients presenting with chest pain. We are doing it in a way that is better for patients, healthcare professionals and health systems. Artrya's software-as-a-medical-device, Salix Coronary Anatomy, is an AI-based solution that quickly analyzes cardiac CT scans to assist clinicians in accurately determining the extent of atherosclerotic plaque as well as plaque characteristics for patients who may be at risk of heart attack.


Sign up to receive investor communications


icon

Company Details

  • Name: Artrya Limited
  • Incorporated: ACN 624 005 741
  • Business description: AI-based coronary artery disease Diagnostic support software
  • Registered office: 1257 Hay St West, Perth, Western Australia, 6005
  • Auditor: KPMG. 235 St George's Terrace, Perth, WA, 6000
  • Contact: investors@artrya.com
icon

Company Contacts

Connect with us and learn more about how Artrya is shifting the paradigm of coronary artery disease diagnosis.

Contact us today